Comparison Between Intraligamentary Piroxicam and Articaine

Pulpitis - Irreversible Clinical Trial

Official title: Comparative Evaluation of the Efficacy of Intra-ligamentary Injection of 20 Milligram (Mg) Piroxicam Versus 4% Articaine in Management of Endodontic Pain in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars

Status Not yet recruiting

Clinical Trial Summary

Comparing the efficacy of intra-ligamentary Piroxicam and intra-ligamentary Articaine on pain during and after endodontic treatment of mandibular molars with symptomatic irreversible pulpitis.

Clinical Trial Description

Owing to the painful nature of endodontic treatment in teeth with symptomatic irreversible pulpitis and difficulty in achieving effective anesthesia particularly in mandibular molars due to various factors such as different bony landmarks, anatomical variations, needle deflection, accessory innervation, so local anesthesia isn't enough in such cases. Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral Piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment. It is also postulated that the intraligamentary injection enables the application of anti-inflammatory agents in the periapical intraosseous region. Moreover, intra-ligamentary injection of local anesthesia was reported to be an effective and easy way to control severe pain during endodontic treatment mainly in mandibular teeth which are more difficult than maxillary teeth , thus piroxicam may be effective as an adjuvant drug to support the action of local anesthetics. ;

Related Conditions & MeSH terms

• Pulpitis
• Pulpitis - Irreversible

• NCT number: NCT03612323
• Study type: Interventional
• Source: Cairo University
• Contact: Lobna Elhadad, student
• Phone: +201279811117
• Email: lobna.elhadad@dentistry.cu.edu.eg
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: November 2018
• Completion date: August 2019